Targeting β-catenin: PROTACs and precision degraders for Wnt-driven cancers

Area of Science:

• Molecular Biology
• Biochemistry
• Oncology

Background:

• The Wnt signaling pathway is essential for embryonic development, cell differentiation, and proliferation.
• Dysregulation of Wnt signaling is implicated in various diseases, particularly cancer.
• Current FDA-approved drugs do not effectively inhibit the Wnt pathway, especially targeting downstream effectors.

Purpose of the Study:

• To review the challenges associated with targeting the downstream Wnt effector, β-catenin.
• To explore current therapeutic strategies aimed at inhibiting β-catenin.
• To provide insights into overcoming on-target toxicity linked to cadherin-bound β-catenin.

Main Methods:

• Literature review of Wnt signaling pathway research.
• Analysis of current drug development approaches targeting β-catenin.
• Examination of toxicity mechanisms and potential solutions.

Main Results:

• Most Wnt inhibitors target upstream components, not the frequently mutated downstream proteins like β-catenin.
• Developing drugs that target β-catenin is a significant area of interest due to its role in disease.
• On-target toxicity associated with cadherin-bound β-catenin presents a major hurdle for therapeutic development.

Conclusions:

• Targeting downstream Wnt effectors, specifically β-catenin, is a promising strategy for cancer therapy.
• Overcoming toxicity issues related to β-catenin inhibition is critical for clinical success.
• Further research is needed to develop safe and effective Wnt pathway inhibitors.